Passage Bio Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good morning. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to have Passage Bio with us. We have Bruce Goldsmith, Chief Executive Officer; and Richard Morris, Chief Financial Officer.
Questions & Answers
And with that, given Passage just completed its IPO in February, could you please walk us through the Passage story and where it stands?
Yes, Salveen, thanks for the opportunity to participate in the conference, and thanks for hosting us.
So the way we view Passage Bio is that we are positioned to become the premier genetic medicines company. And it's really based on what we see as a differentiated approach developing treatments for rare monogenic CNS disorders and an extremely deep pipeline that we've built through an
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |